Navigating Whether to Oppose, Litigate or Settle in Modern Patent Disputes

20 Jan 2027
Pharma & Biotech Patent Litigation Europe

This session unites in-house leaders and private practice experts to discuss the strategic factors shaping modern patent dispute resolution in Europe and internationally. From early-stage decisions around whether to oppose a patent through to litigation tactics, forum selection and settlement strategy, panellists in this session will explore how companies can fine-tune their approach within an increasingly complex patent enforcement landscape.  

 

- Discuss key considerations that shape whether companies oppose, litigate or settle patent disputes, including product pipeline maturity, commercial objectives and evidential readiness.  

- Assess how timing, cost, procedural considerations and the nature of single versus multi-patent disputes influence decision-making around pursuing opposition proceedings versus litigation.  

- Examine how companies are distinguishing between global forums and deciding where to litigate first.  

- Review the risks and strategic advantages associated with pursuing settlement in patent disputes, and discuss how the speed of the UPC is influencing global settlement dynamics.  

- Learn how parallel proceedings can be structured across the UPC, EPO and national courts across jurisdictions to strengthen negotiation positions and support commercially favourable outcomes.  

Speakers
Carsten Richter
Carsten Richter, Head of Intellectual Property Division - Euroimmun
Jennifer Sunderland
Jennifer Sunderland, Senior Patent Litigation Counsel - Viatris
Alexander Daschner
Alexander Daschner, Director Patent Attorney - Fresenius Kabi